Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. (LPCN) furnished an 8-K announcing it issued a press release with financial and operational results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and incorporated by reference. The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act.
Lipocine Inc. reported Q3 2025 results, highlighting modest royalty revenue and higher R&D investment as it advances its pipeline. Revenue was $114,574 for the quarter, driven by royalties, with nine‑month revenue of $831,287. The company posted a Q3 net loss of $3,186,832 and a nine‑month net loss of $7,257,421.
Cash and cash equivalents were $3,901,040 and marketable investment securities were $11,230,031 as of September 30, 2025. Management states existing capital resources are expected to fund operations through at least November 6, 2026. Stockholders’ equity was $14,142,048. Shares outstanding were 5,551,931 as of November 5, 2025.
Commercial progress continued under the Verity license for TLANDO, with Q3 royalty revenue of approximately $115,000 and a Canadian NDS filed in June 2025. Year‑to‑date, licensing revenue was $500,000 and royalty revenue was approximately $331,000, reflecting a shift from prior‑year upfront license income. R&D expenses rose to $2,707,777 in Q3, while G&A declined to $767,837. The company also sold 68,691 shares via its ATM program for net proceeds of $217,000 year‑to‑date.
Lipocine Inc. filed an 8-K stating it issued a press release announcing presentation of LPCN 2401 clinical data at ObesityWeek in Atlanta, GA, held November 4–7. The company furnished the press release as Exhibit 99.1, incorporating it by reference. This is a disclosure of a scientific presentation and does not detail financial metrics or transactions.
Lipocine Inc. filed a current report describing a new press release about the company’s drug candidate LPCN 1154. The release provides a progress update on the ongoing Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The report itself does not detail the trial results or timelines but directs readers to the attached press release, which is included as an exhibit and incorporated by reference.
Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and other audiences. The update reflects the current status of LPCN 2401, a program being developed as an adjunct to GLP-1 therapy.
The company has received IND clearance to proceed with a proof-of-concept study of LPCN 2401, but is first seeking regulatory clarity on the development path, including study endpoints such as functional loss, before moving forward with the study. The revised investor presentation has been filed as Exhibit 99.1 to this report.
Lipocine Inc. filed a current report to announce that the company will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference. The event is scheduled for September 8–10, 2025, in New York City. The company furnished a press release with additional details as Exhibit 99.1 to the report.
Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated September 5, 2025. The filing does not include earnings, financial tables, or other material transaction disclosures; it documents public investor-facing presentation materials being made available.
Lipocine Inc. reported that scientific abstracts related to its program designated LPCN 2101 have been accepted for presentation at the 2025 American Epilepsy Society annual meeting. The conference is scheduled for December 5–9, 2025, in Atlanta, Georgia. Lipocine furnished the related press release as Exhibit 99.1 to this report.
Lipocine Inc. (LPCN) – Q2 2025 10-Q snapshot
For the quarter ended 30 Jun 2025, revenue jumped to $0.623 M (vs $0.090 M LY) on a one-time $0.5 M license payment from newly signed partners, offsetting lower royalties. Operating expenses fell 10% YoY to $3.0 M, led by a 41% drop in G&A, but R&D rose 14% to support LPCN 1154 and other pipeline programs. Net loss narrowed to $2.21 M (-$0.41 EPS) from -$3.07 M (-$0.57 EPS).
Six-month results were weaker: revenue fell 91% YoY to $0.717 M as the prior-year period contained a $7.5 M Verity up-front; net loss swung to $4.07 M (-$0.76 EPS) from a $0.45 M profit. Operating cash burn was $3.9 M; cash & treasury bills ended at $18.6 M (cash $6.0 M, securities $11.9 M) versus $22.5 M 12/31/24. Management projects liquidity through at least Aug 2026 but continues to access an ATM facility (23,739 shares sold for $0.08 M during Q2).
- Total liabilities remain low at $1.45 M; equity fell to $17.1 M.
- New Aché license (Brazil) plus earlier SPC (South Korea) and Pharmalink (GCC) deals expand TLANDO ex-US footprint; up to $259 M in contingent milestones remain unrealized.
- Authorized shares cut to 75 M; 5.42 M shares outstanding.
- No warrants outstanding after 2019/2020 series expired.
Outlook: Near-term revenue hinges on additional license milestones and TLANDO royalties; continued pipeline spend and limited cash generation imply further equity or partnership funding before 2026.